Tumor Localization Articles & Analysis
20 news found
” A pre-clinical-stage company, PanTher Therapeutics is working to revolutionize the treatment of inoperable, locally advanced solid tumors − studying the direct delivery of existing, already proven chemotherapy agents directly onto the tumor for consistent, slow release over time. ...
The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”). ...
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). ...
The results indicate superior tumor killing and persistence of CAR-NK cells as well as optimal activation of other anti-tumor immune cells. ...
Afami-cel SPEAR T-cells target MAGE-A4+ tumors. MAGE-A4 is highly expressed in synovial sarcoma and MRCLS in the context of HLA-A*02. ...
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). ...
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. ...
In pre-clinical studies, TC220 is retained longer in the tumor compared to BPA, making it possible to attain a greater tumor to normal tissue ratio for boron than possible with BPA. ...
GammaTile delivers 50 percent of the radiation within 10 days of resection, which we believe maximizes patient outcomes while improving local tumor control and access to care. We are pleased to partner with Novocure in this pursuit.” About Tumor Treating Fields Tumor Treating Fields, or TTFields, are electric fields that ...
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors Data is currently being presented at the ...
Our portfolio comprises differentiated products that are all delivered systemically but act locally within the tumor. At PsiOxus we are advancing our pipeline of clinical and preclinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring these tumor re-engineering products to patients. About ...
Sloan, the Director of the Brain Tumor Program. Over 400,000 patients are living with a brain tumor in the U.S. each year. The previous standard of care for patients with operable brain tumors is the surgical removal of the tumor followed by adjuvant therapy, including radiation and chemotherapy. ...
Sloan, the Director of the Brain Tumor Program. Over 400,000 patients are living with a brain tumor in the U.S. each year. The previous standard of care for patients with operable brain tumors is the surgical removal of the tumor followed by adjuvant therapy, including radiation and chemotherapy. ...
This registry will shed further light on the real-world benefits of STaRT for people with brain tumors." The multicenter observational study will enroll 600 patients with brain tumors of any pathology who have received treatment with GammaTile Therapy. ...
” As a global provider of breast cancer solutions, Dilon’s Navigator® Gamma Probes are used for radio-guided lymphatic mapping and tumor localization world-wide. “The combination of Dilon’s class leading Navigator® Gamma Probes with the MarginProbe® is a natural fit. ...
The Phase 1 STAR study is being conducted at multiple cancer centers in the United States and will assess the safety, tolerability and preliminary anti-tumor activity of NG-641 in subjects with solid tumors. The ClinicalTrials.gov identifier for the NG-641 study is: NCT04053283. ...
The MOZART® System from KUBTEC Medical Imaging stands alone as it identifies the exact location of three dimensional objects such as tumors and localization devices inside breast cancer specimens. The VeraForm adaptable tissue marker is a radiopaque, continuous, 3-D marker that is highly visible in imaging such as Mozart and beautifully demonstrates the ...
It’s almost impossible to accurately remove a 3D tumor using limited 2D information from a few points. Now imagine if someone didn’t leave a localization wire for you to follow but instead was kind enough to spiral or wind a filament around the outside edges of the entire tumor. ...
For example, transitioning to a wireless tumor localization approach improves the comfort of his patients by avoiding the painful and cumbersome wire. ...
Armed Poxvirus selectively destroys tumor cells SAN FRANCISCO and YONGIN, South Korea, January 12, 2009 /PRNewswire/ -- Jennerex, Inc. ...